Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial
Treatment with alendronate ( Fosamax (R)) has been shown to significantly reduce the risk of fragility fractures. Cost-effectiveness of treatment was assessed in nine European countries in a Markov model and was generally found to be cost effective in women with a previous spine fracture. Introduction Treatment with alendronate (Fosamax (R)) reduces the risk of osteoporotic fractures at the spine,
